Daurismo
What Daurismo is used for
Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Daurismo
- Active substance
- glasdegib
- Disease area
- Leukemia, Myeloid, Acute
- Medicine group
- Antineoplastic agents
- ATC code
- L01XX63
- Marketing authorisation holder
- Pfizer Europe MA EEIG
- Authorised in the EU since
- 2020
Official information
In the USA
Same active substance: Daurismo
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Daurismo used for?
Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy.
What is the active substance in Daurismo?
Daurismo contains glasdegib.
Who makes Daurismo?
The EU marketing authorisation holder is Pfizer Europe MA EEIG.
Is Daurismo an orphan medicine?
Yes. Daurismo is designated an orphan medicine in the EU, for a rare disease (Leukemia, Myeloid, Acute).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU